| Overview |
| bs-10421R-PE |
| Nemo-like kinase (Thr298) Antibody, PE Conjugated |
| WB |
| Human, Mouse |
| Rat, Cow, Sheep, Pig, Chicken, Rabbit |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human Nemo-like kinase around the phosphorylation site of Thr298 |
| Thr298 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Nucleus |
| Nemo-like kinase Thr298; Nemo-like kinase T298; p-Nemo-like kinase Thr298; p-Nemo-like kinase T298; DKFZp761G1211; FLJ21033; LAK1; Nemo like kinase; Nemo-like kinase; Nlk; NLK_HUMAN; Protein LAK1; Serine/threonine protein kinase NLK; Serine/threonine-protein kinase NLK. |
| Nemo-like kinase (NLK) plays a role in cell fate determination and is required for differentiation of bone marrow stromal cells. It acts downstream of MAP3K7 and HIPK2 to negatively regulate the canonical Wnt/beta-catenin signaling pathway and the phosphorylation and destruction of the MYB transcription factor. It may suppress a wide range of transcription factors by phosphorylation of the coactivator, CREBBP. (referenced from swissprot) |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz